12 weeks treatment with 12 weeks followup
With the blinded group %reduction to 50% is at 4 weeks vs 10 weeks for standard treatment. That will have to reduce further when unblinded.
The trial is 1:1:1 - placebo, vf00102 low dose, vf00102 high dose
The last investor presentation showed 12 weeks standard treatment 55% reduction and blinded result at 70% reduction. When unblinded this should improve and then we will also see low dose vs high dose results, so one may be superior to the other.
https://www.asx.com.au/asxpdf/20180314/pdf/43sdy0hjh5gs7w.pdf
- see slide 13 -
Efficacy Will be achieved with ~ 10% difference e.g. 70% reduction for VF001, 60% for placebo
To me it is looking better that that but happy to hear others opinions